Nephros (NASDAQ:NEPH) Trading 0.7% Higher

Shares of Nephros, Inc. (NASDAQ:NEPHGet Free Report) shot up 0.7% during trading on Wednesday . The company traded as high as $2.09 and last traded at $2.08. 1,769 shares traded hands during mid-day trading, a decline of 90% from the average session volume of 17,031 shares. The stock had previously closed at $2.06.

Wall Street Analyst Weigh In

Separately, Benchmark reiterated a “speculative buy” rating and set a $5.00 price objective on shares of Nephros in a research note on Wednesday, May 15th.

View Our Latest Analysis on NEPH

Nephros Stock Performance

The stock has a fifty day simple moving average of $2.17 and a two-hundred day simple moving average of $2.69. The stock has a market cap of $21.92 million, a price-to-earnings ratio of -14.82 and a beta of 1.19.

Nephros (NASDAQ:NEPHGet Free Report) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.02) earnings per share for the quarter. The business had revenue of $3.52 million during the quarter. Nephros had a negative net margin of 10.23% and a negative return on equity of 17.01%.

Insider Activity at Nephros

In related news, CEO Robert R. Jr. Banks acquired 50,000 shares of the company’s stock in a transaction that occurred on Thursday, May 16th. The stock was acquired at an average price of $2.24 per share, with a total value of $112,000.00. Following the purchase, the chief executive officer now directly owns 70,000 shares in the company, valued at $156,800. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last three months, insiders have purchased 55,000 shares of company stock valued at $123,160. 4.10% of the stock is owned by insiders.

Hedge Funds Weigh In On Nephros

An institutional investor recently bought a new position in Nephros stock. Mesirow Financial Investment Management Inc. purchased a new position in shares of Nephros, Inc. (NASDAQ:NEPHFree Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 15,383 shares of the company’s stock, valued at approximately $34,000. Mesirow Financial Investment Management Inc. owned 0.15% of Nephros as of its most recent filing with the Securities and Exchange Commission (SEC). 41.10% of the stock is owned by institutional investors and hedge funds.

Nephros Company Profile

(Get Free Report)

Nephros, Inc, a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.

Read More

Receive News & Ratings for Nephros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nephros and related companies with's FREE daily email newsletter.